Cancer diagnostics today is a time-consuming process which is still performed manually by pathologists. Mindpeak’s products democratize cancer diagnostics, making it accessible to everyone globally. This helps solving the increasing demand-supply gap in cancer diagnosis. We develop solutions based on advanced artificial intelligence (AI) to achieve this. Our AI analyses histopathological tissue slides within seconds. It finds tumour regions and quantifies biomarkers. Pathologists stay in full control and can accept, correct, or even reject suggestions made by our AI. Patients benefit from increased accuracy and a faster turnaround time as well as reduced costs, while pathologists are relieved from tedious manual work. The key USP of our innovation is its reliability in the clinical context: our AI is robust to the significant variations within and across labs. It can easily be integrated in all clinical environments and works with scanner hardware of all major providers. Through feedback from the pathologist, our AI learns over time and continuously improves its accuracy. In contrast to human analysis, its results are not influenced by external factors and always reproducible.
Our innovative AI solutions lie at the heart of Mindpeak. We are a start-up that builds support tools for cancer diagnostics. The fundamental technology of these tools is our AI. Our first product detects and quantifies tumour cells and hit the market in October 2019. It is the first commercially available product for tumour quantification using AI. Up to now Mindpeak is providing several AI software products for cancer diagnosis and other diseases. As a result, our experience and knowledge base has grown tremendously and will allow us to further develop relevant and innovative AI software to help physicians make treatment decisions and to improve the quality of care. In addition, our first commercial steps with international partners have successfully taught us effective go-to-market strategies and how to involve customers in product development so that in the end both benefit from a successful cooperation. Gaining user acceptance is key to disruptive technologies like our innovative AI. Understanding how to convince and work together with pathologists to use our products puts us in a unique position to become a global AI analysis provider for pathology with high penetration in the international market of digital pathology. So, on the one hand, we have realized high-quality AI software in AIPACA on the technological side, and on the other hand, the commercial side, several resulting products have been clinically CE-validated and brought to market through cooperation with pathologists in AIPACA. As a result, Mindpeak has significantly increased its competitiveness of AI software developed at AIPACA. Due to the current lack of AI applications in diagnostics that are as high quality as Mindpeak's products, we see an opportunity to become a leading international provider of highly accurate and robust AI software for clinical use.
